CervoMed Inc. CRVO
1.55 USD -0.09 (-5.49%)
At closeNov 3, 2026, 7:57 PM EST
1.50 -0.05 -3.23%
After hours · Nov 3, 7:57 PM ET
1.52 Day range 1.70
1.55 52-week range 9.94
- YTD
- -80.38%
- 1 year
- -77.92%
- Market cap
- 23.43M
- Revenue (ttm)
- 10.07M
- Profit margin
- -118.68%
- EPS (ttm)
- -3.03
- Shares out
- 8.25M
- Forward P/E
- -0.87
- YTD return
- -80.38%
- 1-year return
- -77.92%
- Volume
- 350.32K
- Avg volume
- 292.50K
- Open
- 1.64
- Previous close
- 1.64
- Day's range
- 1.52 – 1.70
- 52-week range
- 1.55 – 9.94
- Analysts
- Hold
- Price target
- 20.00 (+1190.3%)
- Earnings date
- Apr 1, 2024
2Y -10.92 (-87.57%)
Key statistics
- Enterprise value
- -28.25M
- PEG ratio
- 0.00
- Price / sales
- 1.81
- Price / book
- 0.40
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 27.10%
- Free cash flow
- -6.64M
- Total cash
- 46.66M
- Total debt
- 0
- Return on equity
- -43.28%
- Short % of float
- 35.80%
- 50-day average
- 10.02
- 200-day average
- 16.41
Analyst view
Consensus: hold
Hold
Price target (mean) 20.00 +1190.3% upside
Now 1.55
- Target (low)
- 4.00
- Target (mean)
- 20.00
- Target (high)
- 34.00
Ratings (0m) 8 2 buy · 5 hold · 1 sell
- Strong buy1
- Buy1
- Hold5
- Sell1
- Strong sell0
Next earnings
Apr 1, 2024
Expected Apr 1, 2024. Consensus EPS estimate -0.445.
Financials — quick view
CRVO Revenue — quarterly 0
CRVO Net income — quarterly -6.57M
CRVO EPS — quarterly -0.64
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.41 | -0.55 | -0.14 | -34.15% |
| Aug 9, 2024 | Jun 1, 2024 | -0.24 | -0.27 | -0.03 | -12.50% |
| May 14, 2024 | Mar 1, 2024 | -0.46 | -0.41 | +0.05 | +10.87% |
| Apr 1, 2024 | Dec 1, 2023 | -0.95 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | -0.95 | -0.70 | +0.25 | +26.32% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Dec 11, 2024 | Canaccord Genuity | main | Buy | Buy |
| Dec 11, 2024 | Chardan Capital | down | Buy | Neutral |
| Dec 10, 2024 | Jones Trading | down | Buy | Hold |
| Dec 10, 2024 | D. Boral Capital | down | Buy | Hold |
| Dec 5, 2024 | HC Wainwright & Co. | init | — | Buy |
About CervoMed Inc.
CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cervomed.com
News
CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB) 
12 Health Care Stocks Moving In Monday's Intraday Session 
CervoMed Shows Progress in Treating Rare Aphasia Condition 
CervoMed Shows Progress in Treating Rare Aphasia Condition - 12 Health Care Stocks Moving In Monday's Pre-Market Session
CervoMed Announces Data From Its Phase 2a Clinical Study Of Nonfluent Variant Primary Progressive Aphasia Shows Reduction In Mean Plasma Levels Of Neurofilament Light Chain 
CervoMed (NASDAQ:CRVO) Earns “Buy” Rating from HC Wainwright 
HC Wainwright & Co. Reiterates Buy on CervoMed, Maintains $25 Price Target 
CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of “Moderate Buy” from Brokerages 
CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
Your note
Sign in to keep a note on CRVO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALAM JOHN J | Chief Executive Officer | Stock Gift | Nov 8, 2023 | 1,461,580 |
| BOGER JOSHUA S | Director and Beneficial Owner of more than 10% of a Class of Security | Sale | Feb 25, 2024 | 0 |
| COBUZZI ROBERT JOSEPH JR | Chief Executive Officer | Conversion of Exercise of derivative security | Jan 30, 2023 | 1,616 |
| ELDER WILLIAM ROBERT | General Counsel | Purchase | Aug 26, 2024 | 1,267 |
| GREGOIRE SYLVIE L | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Gift | Nov 8, 2023 | 1,461,580 |
| HOLLINGSWORTH JANE H | Director | Conversion of Exercise of derivative security | Aug 30, 2023 | 898 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 9.90% | 817,120 | 1.81M | Sep 29, 2024 |
| AWM Investment Company, Inc. | 5.44% | 449,006 | 992.30K | Sep 29, 2024 |
| Armistice Capital, LLC | 4.87% | 402,000 | 888.42K | Sep 29, 2024 |
| Vanguard Group Inc | 4.85% | 400,299 | 884.66K | Sep 29, 2024 |
| Blackrock Inc. | 3.86% | 318,766 | 704.47K | Sep 29, 2024 |
| Ikarian Capital, LLC | 2.45% | 202,345 | 447.18K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.19% | 263,000 | 581.23K | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.55% | 127,944 | 282.76K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.09% | 89,787 | 198.43K | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.67% | 55,404 | 122.44K | Aug 30, 2024 |
| iShares Russell 2000 Growth ETF | 0.58% | 48,049 | 106.19K | Oct 30, 2024 |
| Fidelity Extended Market Index Fund | 0.31% | 25,890 | 57.22K | Oct 30, 2024 |